

**Title: Study on the mucosal and serological immune response to the Novel Coronavirus  
(SARS-CoV-2) vaccines**

Renee WY Chan<sup>1,2,3,4\*</sup>, Shaojun Liu<sup>1,2,3,4</sup>, Jonathan Y Cheung<sup>1,2,3,4</sup>, Joseph GS Tsun<sup>1,2,3,4</sup>, Kate C Chan<sup>1,2</sup>, Kathy YY Chan<sup>1,2</sup>, Genevieve PG Fung<sup>1</sup>, Albert M Li<sup>1,2,4</sup>, Hugh Simon Lam<sup>1,2\*</sup>

<sup>1</sup> Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.

<sup>2</sup> Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.

<sup>3</sup> CUHK-UMCU Joint Research Laboratory of Respiratory Virus & Immunobiology, Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.

<sup>4</sup> Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong SAR.

\*Corresponding Authors

Renee Wan Yi Chan, PhD, MPhil, BSc

Assistant Professor, Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong

Corresponding Address: Lab D, 8/F Tower A, The Hong Kong Children's Hospital, Kowloon Bay, Kowloon, HONG KONG

Office Phone: 852+3513-3175

Office Fax: 852+2636-0020

Email: [reneewy@cuhk.edu.hk](mailto:reneewy@cuhk.edu.hk)

Hugh Simon Lam, BChir (Cantab), MB (Cantab), MD (CUHK), MRCPCH (UK), FHKCPaed,  
FHKAM (Paediatrics), FRCPCH (UK)

Professor, Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong  
Kong

Corresponding Address: 6/F Lui Chee Woo Clinical Sciences Building

Office Phone: 852+3505-2851 Office Fax: 852+2636-0020

Email: [hshslam@cuhk.edu.hk](mailto:hshslam@cuhk.edu.hk)

1 **One Sentence Summary:**

2 mRNA vaccine (CoronaVac) elicits mucosal IgA and IgG in the nasal epithelial lining fluid  
3 together with ELISA-detected anti-wild-type spike neutralizing antibodies as early as day 14 post  
4 vaccination.

5  
6 **Abstract**

7 Vaccines that elicit mucosal immune responses against SARS-CoV-2 could potentially be of  
8 exceptional importance in providing first line defense at the site of viral entry. The serological  
9 antibody response induced by SARS-CoV-2 vaccines have already been well characterized. In  
10 order to understand the mucosal immune response profiles of SARS-CoV-2 vaccines, we  
11 examined both the mucosal and systemic responses of subjects vaccinated by two different  
12 vaccination platforms: mRNA (Comirnaty) and inactivated virus (CoronaVac). Serial nasal  
13 epithelial lining fluid (NELF) and peripheral blood samples were collected in ten subjects who  
14 had received CoronaVac and thirty-two subjects who had received Comirnaty. We quantified  
15 IgA and IgG specific to SARS-CoV-2 S1 protein by ELISA in NELF and plasma samples. The  
16 neutralization effect of these two sample types were evaluated by surrogate ACE-SARS-CoV-2  
17 Spike protein ELISA. Only Comirnaty induced nasal SARS-CoV-2 S1 protein-specific (S1-  
18 specific) IgA and IgG responses, which were evident as early as on  $14 \pm 2$  days after the first  
19 dose. The NELF samples of 72% of subjects became IgA+IgG+, while in 62.5% of subjects the  
20 samples were neutralizing by  $7 \pm 2$  days after the second dose. In 45% of the subjects their NELF  
21 remained neutralizing 50 days after the booster of Comirnaty. In plasma, 91% and 100%  
22 Comirnaty subjects possessed S1-specific IgA+IgG+ on  $14 \pm 2$  days after the first dose and  $7 \pm 2$   
23 days after booster, respectively. The plasma collected on  $7 \pm 2$  days after booster was 100%

24 neutralizing. The induction of S1-specific antibody by CoronaVac was IgG dominant, and 70%  
25 of the subjects possessed S1-specific IgG by  $7\pm 2$  days after booster and were all neutralizing.  
26 This study reveals that Comirnaty is able to induce S1-specific IgA and IgG response with  
27 neutralizing activity in the nasal mucosa in addition to a consistent systemic response. The  
28 clinical implications and the biological mechanism of an additional nasal immune response  
29 induced by vaccines such as Comirnaty warrant further investigation.

30 **INTRODUCTION**

31 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes the  
32 coronavirus disease 2019 (COVID-19) pandemic that has resulted in significant morbidity and a  
33 global death toll of over 3 million (1).

34  
35 Among the various COVID-19 vaccines currently authorized by the World Health Organization  
36 (WHO), CoronaVac by Sinovac Biotech and BNT162b2 (aka Comirnaty) from Pfizer-BioNTech  
37 have been approved for emergency use in Hong Kong. These two vaccines utilize different  
38 technological platforms, namely inactivated whole virus and messenger RNA (mRNA) encoding  
39 the full-length viral spike (S) protein modified by two proline mutations, respectively (2). The S-  
40 protein of SARS-CoV-2 is composed of the subunits S1 and S2, with S1 bearing the receptor-  
41 binding domain (RBD) that recognizes host angiotensin-converting enzyme 2 (ACE2) to initiate  
42 viral entry (3, 4) and S2 being responsible for membrane fusion (3). Both vaccines have good  
43 safety records with low prevalence of serious adverse events (5-7). CoronaVac has been shown  
44 to prevent symptomatic COVID-19 in 51% of vaccinated healthcare workers, and an efficacy of  
45 100% in preventing severe COVID-19 (8). Comirnaty is reported to be 95% effective in  
46 preventing symptomatic COVID-19 with low incidence of serious adverse events (5).

47  
48 Mechanistic properties of these novel vaccines in conferring immunity to combat COVID-19 are  
49 beginning to emerge. It has been shown that by 14 days after the booster dose, recipients of  
50 CoronaVac aged 18-50 years had seroconversion rates of 95.6% and 95.7% for S1-RBD IgG and  
51 neutralizing antibodies, respectively (9). In comparison, specific IgG against S1 and RBD of  
52 SARS-CoV-2 are detectable in serum at 21 days after the priming dose of Comirnaty, with 100%

53 seroconversion rate (10). Due to the differences in the study design, it would be difficult to  
54 compare the seroconversion times for both SARS-CoV-2 S1 protein-specific (S1-specific) IgG  
55 and SARS-CoV-2 neutralization between the two vaccines. It is also important to note that due to  
56 differences in the stages of vaccine development, there is currently more research data available  
57 for the mRNA vaccines (e.g., Comirnaty and Moderna) than inactivated viral vaccines (e.g.,  
58 CoronaVac).

59  
60 Comirnaty and Moderna elicit neutralizing antibody (NAb) responses that target the RBD  
61 epitopes in the same manner as natural infections (11). Albeit at much lower titers than IgG  
62 levels, the mRNA vaccines also induce IgM and IgA responses against S-protein and RBD in  
63 plasma samples (11). In the sequence of seroconversion, IgM responses are first generated and  
64 then class-switch converted to IgA and IgG (12). As detectable IgM levels after vaccinations are  
65 often significantly lower and less sustained when compared to IgA and IgG levels, IgM is  
66 suspected to have lesser importance in virus neutralization *in vivo* (11, 13). On the other hand,  
67 serum RBD IgA from COVID-19 patients has been found to have more potent neutralization  
68 potential than paired IgG (14). SARS-CoV-2 IgA can be sustainably elevated in serum or plasma  
69 samples for over 2 months after Comirnaty vaccination (13). Thus, the importance of systemic  
70 SARS-CoV-2 IgA in vaccine-induced immunity against COVID-19 warrants further validation  
71 (13, 15).

72  
73 Since SARS-CoV-2 infects the upper respiratory tract initially, local neutralizing antibodies  
74 could provide substantial protection against infection. In saliva of COVID-19 patients, SARS-  
75 CoV-2 IgA levels was found to be higher than IgG, with neutralization activity correlating with

76 IgA titers, but not IgG (14). Natural infection induces mucosal antibodies directed against S-  
77 protein and RBD, and it has been suggested that higher antibody levels correlated with fewer  
78 systemic symptoms and reduced viral load (16). Thus, respiratory mucosal immunity could have  
79 unique and specific roles in offering protection against SARS-CoV-2 infection (17).

80  
81 Secretory IgA (SIgA) is the most abundant immunoglobulin expressed on mucosal surface and  
82 serves as the first line of defense against infection (14). SIgA in the upper respiratory tract is  
83 from the IgA-secreting plasma cells (18). Whilst it is possible for systemic IgG-producing B  
84 cells to contribute the IgG in the respiratory tract, circulating monomeric IgA cannot be readily  
85 transported into secretions, suggesting that there are distinct systemic and mucosal responses to  
86 SARS-CoV-2 (14). Currently little is known about the mucosal immunity induced by SARS-  
87 CoV-2 vaccinations.

88  
89 To date, one study has reported that mRNA vaccines induce detectable levels of salivary IgA and  
90 IgG responses to the S-protein and RBD of SARS-CoV-2, but their capability for viral  
91 neutralization are unknown (19). Determining whether or not current vaccines induce antibody  
92 response in the mucosa, and if so, the duration and sustainability of any such response in the  
93 context of concurrent data on systemic immunity from plasma samples of vaccinated individuals  
94 can provide invaluable information that can help optimize the use of these vaccines in a range of  
95 public health strategies and in different community settings.

96  
97 The lack of sampling standardization and validation of the mucosal fluid measurements were the  
98 major challenges in the past. Our recent work using nasal strips to collect nasal epithelial lining

99 fluid (NELF) in SARS-CoV-2 infected children and adults is non-invasive and facilitates the  
100 collection of undiluted NELF for SARS-CoV-2 nucleoprotein gene detection (20). The same  
101 method was adopted for the mucosal antibody analysis in the current study. With the possibility  
102 that subjects vaccinated with mRNA vaccine could induce salivary IgA against SARS-CoV-2  
103 protein, we hypothesize that it might also induce SARS-CoV-2 S-protein specific antibody in  
104 other mucosal surfaces. Here, we compared the serological and mucosal immune responses after  
105 vaccination with CoronaVac and Comirnaty with a particular focus on S1-specific IgA levels  
106 detected and neutralization capacity in NELF and plasma.

107 **RESULTS**


108

109 **Demographic of the subjects**

110 Forty-two subjects were recruited in this study. The median age of all subjects was 41 years old  
111 (range 21-74), 40.3% were male. Longitudinal measurements of vaccine induced S1-specific IgG  
112 and IgA in serum and NELF at four time points (**Figure 1A**), 0 to 2 days before the first dose  
113 (Baseline), 14±2 days after the first dose (V+D14), 7±2 days after the booster dose (B+D7) and  
114 any time between 14 days after the booster dose and before 3 months after the first dose (**Figure**  
115 **1A**) were conducted. The median age was significantly different in subjects from the two vaccine  
116 groups, CoronaVac (n=10, median age 59) and Comirnaty (n=32, median age 39.5) ( $p=0.0004$ ).  
117 All subjects declared that they did not have known unprotected exposure to SARS-CoV-2  
118 infected subjects. To ensure that the measurements of the change in SARS-CoV-2 specific  
119 immunoglobulin levels were not due to active SARS-CoV-2 infection during the study period, all  
120 the NELF samples were tested negative for the presence of SARS-CoV-2 nucleoprotein gene. As  
121 a result of the limited number of CoronaVac subjects and the detected difference in age, fifteen  
122 additional subjects who received CoronaVac were recruited for sampling at the 4th time point  
123 (**Figure 1B**). Among them, 43 subjects completed the questionnaire after vaccination to report  
124 any local or systemic events (**Supplementary Table 1**).

125

126



127

128 **Fig 1. Study design and demographics.**

129 (A) There were three standard sampling timepoints and one extended sampling timepoint (4<sup>th</sup>  
 130 sampling) of biological sample collection: (i) 0 to 2 days before the first vaccination (Baseline),  
 131 (ii) 14±2 days after the first vaccination (V+D14), (iii) 7±2 days after booster (B+D7) and (iv)  
 132 any day between 14 days after booster and before 3 months after the first vaccination. (B)  
 133 Subjects vaccinated with CoronaVac (n=10, pink table) and Comirnaty (n=32, grey table) were  
 134 recruited and followed longitudinally, there was a significant difference in their age distributions  
 135 ( $p = 0.0004$ , Mann Whitney test, two-tailed) and so fifteen extra subjects vaccinated with  
 136 CoronaVac were recruited to enrich the data for the 4<sup>th</sup> timepoint.

137 **Comirnaty induced detectable immunoglobulin in NELF**

138 Among the ten subjects who have taken CoronaVac, none of them developed detectable NELF  
139 SARS-CoV-2 S1-specific IgA and IgG (**Figure 2A**) by day  $7\pm 2$  days after booster, while most  
140 subjects who received Comirnaty developed S1-specific antibodies. The elevations in S1-specific  
141 IgA and IgG levels detected in NELF along the three time points were significant by two-way  
142 ANOVA followed by Tukey's multiple comparisons test (**Figure 2D**). Moreover, S1-specific  
143 IgA appeared earlier than IgG in NELF. More subjects developed NELF S1-specific IgA 15/32  
144 (46.9%) than IgG 3/32 (9.4%) (**Supplementary Figure 1B, blue dots**) by  $14\pm 2$  days after the  
145 first vaccination. The proportion of subjects who had received Comirnaty were positive for  
146 NELF S1-specific IgA and IgG increased to 26/32 (81.3%) and 23/32 (71.9%), respectively, by  
147  $7\pm 2$  days after the booster dose (**Supplementary Figure 1C, blue dots**).

148


149 **SARS-CoV-2 IgA appeared earlier than IgG in plasma**

150 In the CoronaVac group, plasma S1-specific IgA increased significantly by  $14\pm 2$  days after the  
151 first vaccination dose and  $7\pm 2$  days after the booster dose (**Figure 2B, green dots**), while the  
152 significant increase in S1-specific IgG was only detected between baseline and  $7\pm 2$  days after  
153 booster (**Figure 2B, orange dots**). On  $7\pm 2$  days after booster, 7/10 (70%) of the CoronaVac  
154 subjects had detectable plasma S1-specific IgG.

155 In the Comirnaty group (**Figure 2E**), 93.8% and 100% of subjects were positive for both plasma  
156 S1-specific IgA and IgG by  $14\pm 2$  days after the first vaccination dose (**Supplementary Figure**  
157 **1B, red dots**) and  $7\pm 2$  days after the booster dose (**Supplementary Figure 1C, red dots**),  
158 respectively. The outliers were contributed by three subjects who were IgA-IgG+ (Subject 40),

159 IgA+IgG- (Subject 11) and IgA-IgG- (Subject 20). Nevertheless, all plasma samples were  
160 IgA+IgG+ by  $7\pm 2$  days after booster.

161 There were no statistically significant correlations between age and the induced NELF and  
162 plasma S1-specific IgA and IgG levels in the longitudinal CoronaVac and Comirnaty recipients  
163 (**Supplementary Figure 2**). However, female subjects who received Comirnaty had higher  
164 plasma S1-specific IgG at the  $14\pm 2$  days timepoint than male subjects ( $p = 0.007$ )  
165 (**Supplementary Figure 2D**).



166  
167 **Fig 2. Expression of NELF and plasma SARS-CoV-2 S1-specific IgA and IgG and**  
168 **neutralizing antibody (NAb).**

169 The level of S1-specific IgA (green dots) and IgG (red dots) were plotted against the three  
170 standard timepoints of sample collection in NELF (**A and D**) and plasma (**B and E**) specimens  
171 of the recipients of CoronaVac (**A and B**) and Comirnaty (**D and E**). Data points above the  
172 dotted line (Sample/Calibrator (S/C) ratio  $\geq 1.1$ ) are considered as positive, while the dotted lines  
173 at  $y=15$  indicate the upper detection limit of the assay. Asterisks indicate statistical significance  
174 between timepoints of the same Ig class by two-way repeated-measures ANOVA followed by

175 Tukey's multiple comparison test. \*\*:  $p < 0.001$ , \*\*\*:  $p < 0.0002$  and \*\*\*\*:  $p < 0.0001$ . The  
176 percentage of signal inhibition observed with the surrogate SARS-Co-V 2 neutralization  
177 antibody detection kit by the NELF and plasma samples of CoronaVac (C) and Comirnaty (F)  
178 recipients collected on  $7 \pm 2$  days after booster were plotted. The 30% signal inhibition cutoff for  
179 SARS-CoV-2 NAb detection is interpreted as the sample containing neutralizing antibodies for  
180 SARS-CoV-2.


## 181 **Neutralization potential of NELF and plasma**

182 We further tested whether NELF and plasma samples were SARS-CoV-2 neutralizing by using  
183 the blocking enzyme-linked immunosorbent assay as a surrogate of the neutralization test. NELF  
184 and plasma samples collected at  $7\pm 2$  days after booster were measured. In the CoronaVac group,  
185 as there were no SARS-CoV-2 S1-specific IgA and IgG detected in the NELF, we did not  
186 perform NAb measurement for those samples. Whereas 7/10 of the plasma from CoronaVac  
187 subjects contained SARS-CoV-2 NAb. In the Comirnaty group, 20/32 NELF samples inhibited  
188 the binding of SARS-CoV-2 spike protein to ACE-2 (**Figure 2F**), whereas all plasma samples  
189 provided over 80% inhibition to the binding of SARS-CoV-2 spike protein to ACE-2.

190

## 191 **The correlation between SARS-CoV-2 S1-specific Ig with neutralization antibody level**

192 In the CoronaVac group, no significant correlations were found between the plasma IgA and IgG  
193 levels with the percentage of binding inhibition (**Figure 3A**). In the Comirnaty group, significant  
194 correlations were found between the S/C ratio of NELF IgA ( $r=0.509$ ,  $p=0.031$ ), NELF IgG  
195 ( $r=0.777$ ,  $p<0.0001$ ) (**Figure 3B**) and plasma IgA ( $r = 0.634$ ,  $p=0.008$ ) levels and the percentage  
196 of binding inhibition (**Figure 3C**).



197

198 **Fig 3. Correlation of SARS-CoV-2 S1-specific Igs to the percentage of signal inhibition in**  
199 **the surrogate ACE-2 based neutralization readout.**

200 The correlation coefficients of the S/C ratio of the (A) plasma of CoronaVac subjects, (B) NELF  
201 and (C) plasma of Comirnaty subjects at  $7 \pm 2$  days after booster are superimposed on the panel  
202 with trend lines estimated with the use of simple linear regression. Plots show the S/C ratio of the  
203 SARS-CoV-2 S1-specific IgA (green dots) and IgG (orange dots) between  $\geq 1.1$  to  $< 15$  were  
204 plotted against the percentage of inhibition of the SARS-CoV-2 Spike-ACE-2 binding signal, in  
205 which an inhibition  $\geq 30\%$  is regarded as the threshold of a positive sample, indicated by the  
206 vertical dotted line. Data with negative result in either one test were excluded from the two-tailed  
207 Spearman correlation analysis. Green and orange dotted lines represent significant linear  
208 regression fits with 95% confidence intervals (shaded region with the corresponding colors).

209 **Neutralizing antibody in NELF is transient**


210 Whether this is a transient expression SARS-CoV-2 NAb in NELF is uncertain, as there were  
211 five individuals (subjects 9, 33, 34, 37, 41) showing a downward trend of S/C ratio of IgA from  
212  $14\pm 2$  days after the first vaccination to  $7\pm 2$  days after booster (**Supplementary Figure 2A**). The  
213 longevity of the NAb in NELF was further assessed in 11/32 Comirnaty subjects who had  
214 reached the 4<sup>th</sup> sampling time point, i.e. any time after 14 days post-booster and before 3 months  
215 post-vaccine (**Figure 4A**). Only three NELFs still contained NAb, while two of them became  
216 NAb negative. Nevertheless, a late NELF NAb development was observed in two individuals,  
217 who did not possess NELF NAb earlier on  $7\pm 2$  days after booster, though four subjects' NELF  
218 remained negative for NAb. Within these eleven subjects, a significant decrease in the S/C ratio  
219 of the S1-specific IgA was also observed from  $7\pm 2$  days after booster to the 4th sampling time  
220 point ( $p=0.018$ ) (**Supplementary Figure 3**). Lastly, at the 4th sampling time point, the 25  
221 NELFs obtained from the CoronaVac group also underwent the NAb assay, however, none of  
222 them were positive, though one subject from the cross-sectional group had a positive S1-specific  
223 IgA (S/C ratio=1.27) readout.

224

225 **75% NAb detection in CoronaVac subjects' plasma**

226 After  $7\pm 2$  days of the booster 7/10 subjects who had received CoronaVac had NAb (**Figure 4B**),  
227 and five of them remained NAb positive by their 4th sampling time point. With the extended  
228 time after booster, one gained NAb by 24 days after the booster (subject 13) though another  
229 subject did not develop plasma NAb even by 20 days post booster (Subject 14). The differences  
230 in observations in our longitudinal cohort of Sinovac recipients (n=9) from Comirnaty recipients  
231 were unlikely an age effect, as we found that consistent with the longitudinal subjects, 12/15

232 plasma samples from the younger subjects in the cross-sectional group of CoronaVac recipients  
233 had NAb (**Figure 4B, pink dots**). Overall, 75% (18/24) of the recruited subjects had NAb in  
234 their plasma at the 4th sampling time point. Moreover, there were no correlations between NAb  
235 levels either with time post booster ( $p=0.38$ ) or with age ( $p=0.78$ ). In the Comirnaty group, all  
236 subjects had NAb since  $7\pm 2$  days after booster and it lasted at least for 50 days after the booster  
237 dose (**Figure 4C**).



238

239 **Fig 4. Longevity of the NAb in NELF and plasma samples.**

240 (A) The paired-percentage of signal inhibition by the NAb in the NELF from  $7 \pm 2$  days after  
241 booster to the 4th sampling time point of eleven Comirnaty subjects. Data from the samples of  
242 the same individual is joined by a dotted line. (B) The paired-percentage of signal inhibition by  
243 NAb in the plasma from  $7 \pm 2$  days after booster to the 4th sampling time point of CoronaVac  
244 subjects in the longitudinal group ( $n=9$ , red dots) is joined by a dotted line, and each pink dot  
245 represents the percentage of signal inhibition of the plasma samples from CoronaVac recipients  
246 in the cross-sectional group ( $n=15$ ). (C) The paired-percentage of signal inhibition by NAb in the  
247 plasma of eleven Comirnaty subjects from  $7 \pm 2$  days after booster to the 4th sampling time point  
248 is shown.

249

250 **DISCUSSION**

251 Our study reveals that both Comirnaty and CoronaVac induces plasma SARS-CoV-2 S1-specific  
252 IgA and IgG, and NAb. However, Comirnaty, but not CoronaVac, induced S1-specific IgA and  
253 IgG in the nasal mucosa by  $7\pm 2$  days after booster. Of the Comirnaty recipients 72% produced  
254 an NELF antibody response, while 62.5% exhibited neutralizing activities in their NELF  
255 samples. The NAb in NELF correlated with the S/C ratio of the S1-specific IgA and IgG  
256 detected. The induction of nasal S1-specific Igs and NAb is unique to subjects receiving  
257 Comirnaty and it was not found in the NELF of the CoronaVac recipients. The longevity of the  
258 NAb in NELF was assessed in 12/32 Comirnaty subjects who had reached the extended time  
259 point, i.e. any day between 14 days after booster and before 3 months after the first vaccination.  
260 Only three NELFs remained neutralizing, while two of them became NAb negative.  
261 Nevertheless, a late rise in NELF NAb was observed in two individuals who did not possess  
262 NAb in their NELF in the earlier time points. Lastly, four of the Comirnaty recipients remained  
263 NELF NAb negative through all timepoints. From our data, the plasma NAb may last at least 50  
264 days after the booster, though further samples are required to validate this claim.

265  
266 It has been commonly believed that intramuscular vaccines do not induce mucosal immunity  
267 effectively (21). The mucosal immune response of the upper respiratory tract is partly  
268 compartmentalized and usually initiated in nasopharynx-associated lymphoid tissue (NALT) in  
269 all age groups and bronchus-associated lymphoid tissue (BALT) in children and adolescents or  
270 in adults upon disease induction (18). These upper respiratory tract associated lymphoid tissues  
271 generate IgA-producing mucosal B cells that express the homing receptor, e.g.  $\alpha 4\beta 1$ , CCR10,  
272 CD62L and LFA-1 (22, 23). These homing receptors allow the B-cells to traffic efficiently to the

273 mucosal effector site, the respiratory tract in this case, where their ligands VCAM-1 and CCL28  
274 are strongly expressed. The IgA-producing mucosal B cells differentiate into polymeric IgA-  
275 secretory plasma cells and contribute to the production of the polymeric IgA (in dimers or  
276 tetramers) in the lamina propria as opposed to serological IgA (predominantly monomers), which  
277 is produced within bone marrow, spleen and lymph nodes (17). Therefore, SIgA present in  
278 secretions are typically produced within mucosal tissues. This raises important questions about  
279 the route that mRNA-lipid nanoparticles would take from the intramuscular injection site to the  
280 NALT (and BALT) and the biological mechanisms that underlie this process.

281  
282 In an animal study using similar lipid nanoparticles carrying mRNA encoding haemagglutinin  
283 proteins of influenza to investigate the biodistribution of the influenza mRNA in mouse plasma  
284 and tissue after intramuscular administration. It is assumed that the concentration of mRNA lipid  
285 nanoparticles decreases along the disseminating route from the injection site which includes  
286 through the systemic circulation and via the lymphatic system, spleen and liver. It was found that  
287 the expression of mRNA can be detected in distal tissues, including lung, though the  
288 concentration was 1,000 fold lower (24). The same study also showed the presence of mRNA in  
289 the intestine, though they did not test for the presence of such in the airway mucosae. In terms of  
290 the Comirnaty vaccine, the 30-microgram vaccine dose contains approximately 13,000 billion  
291 repetitions of the optimized SARS-CoV-2 Spike protein sequence as documented (2). We  
292 postulate that the number of the mRNA lipid-nanoparticles that reach the nasal mucosa after  
293 Comirnaty injection might be sufficient for NALT stimulation. However, the mechanisms  
294 underlying this process and factors that affect the consistency of this effect requires further  
295 investigation.

296

297 The clinical implication of the induction of nasal SARS-CoV-2 NAb is increased likelihood of  
298 immediate protection at the target site of viral infection. The role that this mucosal immune  
299 response may play in reducing the risk of virus transmission should also be considered.  
300 Sufficiently high concentrations of NAb in the NELF can block the attachment of virus to the  
301 host cell receptor. The SIgA is known to trap virus efficiently and facilitates the removal of such  
302 by the mucociliary beating (25), to neutralize virus particles with epithelial cell and lamina  
303 propria (17), and has anti-inflammatory properties (26).

304

305 We also confirmed the presence of vaccination induced plasma S1-specific IgA and IgG in both  
306 CoronaVac and Comirnaty recipients. For CoronaVac, 70% of the subjects were found to have  
307 NAb by  $7 \pm 2$  days after booster. Whereas all subjects who received two doses of Comirnaty had  
308 NAb in their plasma samples  $7 \pm 2$  days after booster. Of note, at the 4th sampling time point,  
309 73% of the cross-sectional CoronaVac group had plasma NAb (**Figure 4A**, pink dots), which is  
310 similar to the older subjects in the longitudinal CoronaVac group, inferring that age is not a  
311 contributing factor to the NAb level in the CoronaVac group. Therefore, the lower percentage of  
312 plasma NAb detected in CoronaVac than the Comirnaty group cannot simply be explained by the  
313 difference in age.

314

315 The delayed NAb response found in CoronaVac subjects compared with those in Comirnaty  
316 group was not surprising. It has been reported that seroconversion rates were 47.8% and 95.6%  
317 for S1-RBD-specific IgG for CoronaVac at 14 days and 28 days after booster, respectively (9).  
318 Thus, our study design with this interim report at  $7 \text{ days} \pm 2$  post booster may not have

319 demonstrated the full immune responses elicited by CoronaVac. Nevertheless, there were seven  
320 CoronaVac subjects who did not develop NAb in their plasma samples even by the 4th sampling  
321 time point. Three of them were from the longitudinal group in which two of them had their NAb  
322 weaned on 55 and 56 days after booster (Subjects 8 and 5, respectively) while one of them never  
323 exhibited plasma NAb even after 19 days of booster (Subject 14). For the four NAb negative  
324 plasma results contributed by the cross-sectional group, without the baseline measurements, we  
325 cannot conclude whether this was due to a short duration of their NAb responses or if they never  
326 developed a NAb response. The apparent non-responders were subjects L7, L25, L37 and L38 at  
327 their 55, 51, 39 and 25 days after booster, respectively. This might infer the needs of an  
328 additional dose to ensure a sufficient protection to the CoronaVac recipients (27). Moreover,  
329 apart from the humoral response towards spike protein, the development of antibodies against  
330 other viral proteins which have a lower mutation rate, such as nucleoprotein, might be an edge of  
331 CoronaVac over Comirnaty (28). Furthermore, a comprehensive measurement to include the  
332 cellular response induction would provide a balanced information about the overall protection  
333 against SARS-CoV-2 exerted by vaccination (29).

334  
335 Consistent with our findings, Danese *et al.* demonstrated that all SARS-CoV-2 antibodies (IgM,  
336 IgG, IgA) begin to rise from 7 to 11 days post primer dose of Comirnaty and they also showed  
337 that the booster dose of Comirnaty further increases the levels of IgG against S1/S2 and RBD  
338 (13). Both plasma IgG and IgA levels have been found to remain elevated for up to 65 days post  
339 first vaccine dose (13). Whilst Wang *et al.* reported that after receiving two doses of mRNA  
340 vaccines (Comirnaty or Moderna), high levels of IgM and IgG against S and RBD of SARS-  
341 CoV-2 is detectable for up to 8 weeks after booster (11). Furthermore, our study demonstrated

342 the correlation between plasma IgA levels with the percentage of virus-receptor binding  
343 inhibition as reported in a previous study (14). Together, our findings confirm the reliability of  
344 Comirnaty in generating robust humoral immune responses in vaccinated subjects.

345  
346 The presence of nasal mucosal immunoglobulins after vaccination against COVID-19 has not  
347 been previously reported. Whilst we currently have some insights into the durability of  
348 serological IgA and IgG response after Comirnaty vaccination. There is currently no information  
349 on the longitudinal expression of the immunoglobulins in NELF samples representing mucosal  
350 immunity in COVID-19 patients nor recipients of SARS-CoV-2 vaccine. We are now  
351 continuously following these subjects and collecting paired NELF and blood samples at 3, and 6  
352 months after first dose of vaccination to better understand the longevity of mucosal immunity  
353 elicited by intramuscular vaccination. Such findings could have implications on public health  
354 strategies and screening for immunity to enable resumption of normalcy on a global scale.

355  
356 The current study has the following limitations. First, the smaller sample size and the higher  
357 median age of the recipients of CoronaVac in the longitudinal group can be argued to have  
358 contributed towards the absence in NELF response and a slower and milder plasma response  
359 when compared to Comirnaty. We attempted to recruit the cross-sectional subjects to enrich our  
360 data for this important early report, while more subjects would be recruited for a better  
361 comparison. Second, we were using a SARS-CoV-2 surrogate virus neutralization test instead of  
362 a neutralization assay with live cells and viruses in Biosafety Level 3 settings. Therefore, the  
363 NAb measured in this study is a surrogate measure that is solely based on the inhibition of the  
364 binding between the SARS-CoV-2 antibody-mediated blockage of ACE2-spike (RBD) protein-

365 protein interaction (30). The protective effects of the intracellular action of NELF IgA in the  
366 Comirnaty recipients or the plasma Ig specific to other SARS-CoV-2 proteins that theoretically  
367 should be manufactured in CoronaVac recipients were not considered. Although the surrogate  
368 assay used has been validated with the plaque reduction neutralization test (PRNT) utilizing the  
369 SARS-CoV-2 virus (31), the current test could underestimate the actual neutralization capacity.  
370 Third, we observed tremendous individual variations, for example, some recipients of Comirnaty  
371 were found to be IgA-, IgG- or IgA-IgG- for S1 protein. Although Comirnaty induced mucosal  
372 immunoglobulins for 72% of vaccinated subjects, there were individuals who, despite having  
373 plasma S1-specific IgA and IgG, did not express NELF S1-specific IgA (n=2) or IgG (n=5) or  
374 both (n=4). These variations require a larger sample size to further clarify. Nevertheless, our  
375 current study clearly shows qualitative and significant differences in mucosal response between  
376 different vaccine technologies. Lastly, the best available assay for the measurement of SARS-  
377 CoV-2 S1-specific IgA and IgG used in this study was optimized for plasma and serum rather  
378 than mucosal lining fluid. We were therefore unable to differentiate between the monomeric and  
379 dimeric forms of IgA or identify any secretory component in our subjects' NELF samples.

380

## 381 **CONCLUSION**

382 Despite being a vaccine administered via the intramuscular route, Comirnaty, and likely other  
383 mRNA vaccines, uniquely induces SARS-CoV-2 S1 specific IgA and IgG in the nasal mucosal  
384 of vaccine recipients as early as 14 days after the first dose. The NELF neutralizing effect infers  
385 protection from SARS-CoV-2 infection at the level of the upper respiratory epithelium, when the  
386 level of NAb is sufficiently high. This extra arm of protection at the mucosa, on top of the well-  
387 characterized serological antibody development, might further reduce the chance of SARS-CoV-

388 2 infection, in addition to its effectiveness in protecting the recipient from hospitalization and  
389 severe disease. Though the response may be transient, it is possible that a more rapid elevation in  
390 antibodies may occur within the mucosa when the subject is exposed to live viruses, thus  
391 conferring protection from infection even before the virus breaches the mucosa. CoronaVac  
392 vaccine induces an IgG dominant response in the recipients' plasma with neutralizing effect, but  
393 did not produce any mucosal antibody response. The duration required for the plasma Igs and  
394 NAb development observed in our study, is comparable to what has been previously reported,  
395 however, the additional information relating to mucosal response and the direct comparison  
396 between two vaccine technologies provides important insights into how to best utilize these  
397 different vaccines from a public health point of view.

398

## 399 **IMPLICATIONS**

400 This study provides paired data of the mucosal findings and systemic immunological endpoints  
401 of adults before and after receiving the two different SARS-CoV-2 vaccines. The insights gained  
402 from the different immune profiles between inactivated viral vaccines and mRNA vaccines  
403 would be helpful to help optimize public health strategies. While we found that both Comirnaty  
404 and CoronaVac induced systemic humoral responses, Comirnaty likely provides enhanced  
405 mucosal level immune protection and which we postulate could contribute to reduction in  
406 asymptomatic transmission risk. This suggests that Comirnaty may be more suitable for  
407 individuals who are often in close contact with vulnerable and/or unvaccinated individuals (e.g.,  
408 old age home workers, pediatricians, school teachers).

409

410 CoronaVac, on the other hand, induced satisfactory systemic humoral response with neutralizing  
411 capacity induced by CoronaVac in most individuals, and there is less concern about the potential  
412 for unintended inflammatory or immune reactions in organs/tissues distal to the vaccination site  
413 means that CoronaVac may be more suitable for large groups of vulnerable populations who  
414 require protection from SARS-CoV-2. The easier logistics involves in the storage and  
415 distribution of CoronaVac might help to provide a high vaccination coverage within such  
416 vulnerable populations.

417 The unexpected mucosal response in mRNA vaccine recipients raises the concern about which  
418 other organs/tissues may be similarly affected and whether inflammatory/immunological  
419 responses in some tissues may cause unintended side effects with adverse outcomes. Therefore,  
420 this piece of information highlights the necessity in speeding up further studies to determine the  
421 distribution of mRNA lipid nanoparticles in humans. Moreover, the mucosal humoral response  
422 against SARS-CoV-2 S protein is inconsistent between individuals. The publication of this  
423 manuscript will consolidate the collaborative effort among different research groups to  
424 investigate the biological determinant to increase the consistency of mucosal response.

425 Finally, we see a niche for the further development of the antibody detection strategy by using  
426 mucosal lining fluid sample. The current collection method is painless, self-administered and can  
427 be carried out repeatedly in all age groups. The mucosal antibody test would provide the immune  
428 status after vaccination (or by natural infection), with a direct reflection of the protection level at  
429 the site of virus entry.

## 430 **MATERIALS AND METHODS**

### 431 *Subject recruitment*

432 We released the information of this study through the department website, department social  
433 media, The Chinese University of Hong Kong (CUHK) mass mail system, CUHK-online form  
434 and word of mouth to reach potential subjects and arrange the sampling logistics. Subject who  
435 had arranged their own COVID-19 vaccinations with known schedules of vaccine doses were  
436 recruited. All subjects were requested to complete a one-page questionnaire to capture their  
437 demographics, past medical history, drug use and the reporting of any adverse effects after  
438 vaccination or respiratory tract infections within the study period. Consent was obtained from the  
439 participants and the study was approved by the Joint Chinese University of Hong Kong – New  
440 Territories East Cluster Clinical Research Ethics Committee (CREC: 2021.214).

441

### 442 *Clinical sample collection regime*

443 Nasal lining epithelial lining fluid (NELF) from both nares and 3mL peripheral blood were  
444 collected from the subjects at four time points. A pre-vaccination sample pair was collected  
445 during the 48-hour period before the day of vaccination. Three post-vaccination sample pairs  
446 were collected at  $14 \pm 2$  days after first dose and  $7 \pm 2$  days post-booster as in **Figure 1A**. An  
447 extended sampling timepoint (4<sup>th</sup> sampling) of biological sample collection was performed any  
448 day between  $14 \pm 2$  days after the booster and before 3 months after the first vaccination dose, to  
449 assess the intermediate longevity of SARS-CoV-2 specific Ig and NAb responses.

450

### 451 *NELF collection by nasal strips*

452 Strips were cut from sheets of Leukosorb medium (Pall Corporation, BSP0669) using a laser  
453 cutter (CMA960, Department of Biomedical Engineering, CUHK) to the dimensions of 4 mm  
454 wide and 40mm long with a marking at 12mm as previously described (20, 32). 100uL of sterile  
455 saline were instilled in each nostril of the subject. Strips were inserted into the anterior part of the  
456 inferior nasal turbinate of each nostril until the indicator mark was at or close to the base of each  
457 naris. After insertion, the nose was pinched for 1 minute to allow thorough absorption of NELF  
458 by the strip. Strips were removed and eluted within 24h after collection. To elute NELF, strips  
459 were soaked in 300uL PBS on ice for 5 min with a quick vortex. The solution and the strip were  
460 transferred to a Costar Spin-X (CLS9301) and centrifuged twice at 13,000 rpm for 2 min at 4°C  
461 to elute the NELF from the strip into the 1.5-ml tube. The NELF was aliquoted into small  
462 volume vials for downstream analysis of SARS-CoV-2 specific Ig panels and neutralization test  
463 and were stored at -80°C until analysis.

464

#### 465 *Plasma preparation*

466 Blood was collected aseptically by venepuncture and transferred into EDTA blood tube. Plasma  
467 samples were separated by centrifugation at 4°C, 2000g for 20 minutes, aliquoted into small  
468 volume specimens and stored at -20° C until analysis.

469

#### 470 *Measurement of specific IgA and IgG against SARS-CoV-2 Spike protein*

471 Semi-quantitative measurements of SARS-CoV-2 Spike protein (S1 domain) specific Ig ELISA  
472 Kits (Euroimmun, EI 2606-9601 A and EI 2606-9601 G) were used. 1:10 diluted-NELF and  
473 1:100 diluted plasma were added to the assay well and processed as per manufacturer's  
474 instructions. After subsequent wash and incubation steps with conjugates or substrates, the

475 plates were analyzed according to the manufacturer's instructions on the Synergy HTX Multi-  
476 Mode Reader. Semi-quantitative readout as a ratio between the sample and the calibrator optical  
477 density (OD) values was used. The performance was checked by keeping the optical density of  
478 the calibrator within the reference value, and the ratio between the positive and negative controls  
479 between 1.6-4.2 and 0-0.7, respectively.

480

#### 481 *Measurement of SARS-CoV-2 neutralization antibody*

482 A blocking enzyme-linked immunosorbent assay (GenScript, L00847) was employed. Briefly,  
483 NELF, plasma samples and controls were 1:9 diluted and mixed with HRP-RBD solution and  
484 incubated at 37°C for 30 minutes. The mixture was then added to the human ACE-precoated  
485 plate and incubated at 37°C for 15 minutes and processed as per manufacturer's instructions. The  
486 performance was checked by ensuring that the OD<sub>450</sub> must fall below 0.3 for the positive  
487 control and above 1.0 for the negative control. A 30% signal inhibition was set as the cutoff for  
488 SARS-CoV-2 NAb detection.

489

#### 490 *Viral RNA extraction and quantification*

491 To eliminate the possibility of active SARS-CoV-2 infection during the study period, 70uL of  
492 NELF collected at each timepoint were extracted using PHASIFY VIRAL RNA Extraction  
493 Kit™ following manufacturer's instruction. RNA was reconstituted in 20uL of RNase-free  
494 water. 4uL of the RNA sample was used in each reaction, and the SARS-CoV-2 RNA was  
495 quantified by one-step Master Mix (TaqMan Fast Virus, ThermoFisher) with primers and probe  
496 targeting the N gene of SARS-CoV-2 as described (33). Duplicate reaction was conducted on  
497 QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) at

498 the following cycling conditions: reverse transcription at 50°C for 5 min, inactivation of reverse  
499 transcriptase at 95°C for 20s, 40 cycles of PCR amplification (Denaturing at 95°C for 5s;  
500 Annealing/ Extending at 60°C for 30s). No template control and positive control using cell  
501 lysate from SARS-CoV-2 infected human respiratory cells were included in each run.

502

### 503 *Statistical analysis*

504 The demographic variables of subjects were compared between the two vaccinated groups using  
505 the Mann Whitney test and Fisher's exact test, as appropriate. For the immunoglobulin profiles,  
506 differences between different gender and time points were evaluated using Mann Whitney test  
507 and Friedman test followed by Dunn's multiple comparison test, respectively. The correlation of  
508 S/C ratio of the specific immunoglobulins with the percentage of signal inhibition in the  
509 surrogate neutralization test was examined by Spearman's correlation test. Differences were  
510 considered to be statistically significant if  $p < 0.05$ . The All statistical tests were performed using  
511 Graphpad version 9.1.2 for macOS. Differences were considered statistically significant at  $p <$   
512 0.05.

## References

1. WHO Coronavirus (COVID-19) Dashboard (2021 <https://covid19.who.int>).
2. *Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein.* (11889, 2020).
3. L. Dai, G. F. Gao, Viral targets for vaccines against COVID-19. *Nat Rev Immunol* **21**, 73-82 (2021).
4. M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* **5**, 562-569 (2020).
5. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L. Hammitt, O. Tureci, H. Nell, A. Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Sahin, K. U. Jansen, W. C. Gruber, C. C. T. Group, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615 (2020).
6. Z. Wu, Y. Hu, M. Xu, Z. Chen, W. Yang, Z. Jiang, M. Li, H. Jin, G. Cui, P. Chen, L. Wang, G. Zhao, Y. Ding, Y. Zhao, W. Yin, Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*, (2021).
7. Y. Zhang, G. Zeng, H. Pan, C. Li, Y. Hu, K. Chu, W. Han, Z. Chen, R. Tang, W. Yin, X. Chen, Y. Hu, X. Liu, C. Jiang, J. Li, M. Yang, Y. Song, X. Wang, Q. Gao, F. Zhu, Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in

- healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* **21**, 181-192 (2021).
8. R. a. B. Palacios, Ana Paula and Albuquerque, Camila Santos Nascimento and Patiño, Elizabeth González and Santos, Joane do Prado and Tilli Reis Pessoa Conde, Mônica and Piorelli, Roberta de Oliveira and Pereira Júnior, Luiz Carlos and Raboni, Sonia Mara and Ramos, Fabiano and Sierra Romero, Gustavo Adolfo and Leal, Fábio Eudes and Camargo, Luis Fernando Aranha and Aoki, Francisco Hideo and Coelho, Eduardo Barbosa and Oliveira, Danise Senna and Fontes, Cor Jesus Fernandes and Pileggi, Gecilmara Cristina Salviato and Oliveira, Ana Lúcia Lyrio de and Siqueira, André Machado de and Oliveira, Danielle Bruna Leal de and Botosso, Viviane Fongaro and Zeng, Gang and Xin, Qianqian and Teixeira, Mauro Martins and Nogueira, Maurício Lacerda and Kallas, Esper Georges, Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study (April 11, 2021). (2021).
9. S. M. Bueno, K. Abarca, P. A. González, N. M. Gálvez, J. A. Soto, L. F. Duarte, B. M. Schultz, G. A. Pacheco, L. A. González, Y. Vázquez, M. Ríos, F. Melo-González, D. Rivera-Pérez, C. Iturriaga, M. Urzúa, A. Dominguez, C. A. Andrade, R. V. Berrios, G. Canedo-Marroquín, C. Covián, D. Moreno-Tapia, F. Saavedra, O. P. Vallejos, P. Donato, P. Espinoza, D. Fuentes, M. González, P. Guzmán, P. Muñoz-Venturelli, C. M. Pérez, M. Potin, A. Rojas, R. Fasce, J. Fernández, J. Mora, E. Ramírez, A. Gaete-Argel, A. Oyarzún-Arrau, F. Valiente-Echeverría, R. Soto-Rifo, D. Weiskopf, A. Sette, G. Zeng, W. Meng, J. V. González-Aramundiz, A. M. Kalergis, Interim report: Safety and

- immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. *medRxiv*, 2021.2003.2031.21254494 (2021).
10. U. Sahin, A. Muik, I. Vogler, E. Derhovanessian, L. M. Kranz, M. Vormehr, J. Quandt, N. Bidmon, A. Ulges, A. Baum, K. E. Pascal, D. Maurus, S. Brachtendorf, V. Lorks, J. Sikorski, P. Koch, R. Hilker, D. Becker, A. K. Eller, J. Grutzner, M. Tonigold, C. Boesler, C. Rosenbaum, L. Heesen, M. C. Kuhnle, A. Poran, J. Z. Dong, U. Luxemburger, A. Kemmer-Bruck, D. Langer, M. Bexon, S. Bolte, T. Palanche, A. Schultz, S. Baumann, A. J. Mahiny, G. Boros, J. Reinholz, G. T. Szabo, K. Kariko, P. Y. Shi, C. Fontes-Garfias, J. L. Perez, M. Cutler, D. Cooper, C. A. Kyratsous, P. R. Dormitzer, K. U. Jansen, O. Tureci, BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. *Nature*, (2021).
  11. Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, M. Turroja, K. A. West, K. Gordon, K. G. Millard, V. Ramos, J. Da Silva, J. Xu, R. A. Colbert, R. Patel, J. Dizon, C. Unson-O'Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. J. Bjorkman, R. Casellas, T. Hatzioannou, P. D. Bieniasz, M. C. Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* **592**, 616-622 (2021).
  12. Y. X. Chao, O. Rotzschke, E. K. Tan, The role of IgA in COVID-19. *Brain Behav Immun* **87**, 182-183 (2020).
  13. E. Danese, M. Montagnana, G. L. Salvagno, D. Peserico, L. Pighi, S. De Nitto, B. M. Henry, S. Porru, G. Lippi, Comprehensive assessment of humoral response after Pfizer

- BNT162b2 mRNA Covid-19 vaccination: a three-case series. *Clin Chem Lab Med*, (2021).
14. D. Sterlin, A. Mathian, M. Miyara, A. Mohr, F. Anna, L. Claer, P. Quentric, J. Fadlallah, H. Devilliers, P. Ghillani, C. Gunn, R. Hockett, S. Mudumba, A. Guihot, C. E. Luyt, J. Mayaux, A. Beurton, S. Fourati, T. Bruel, O. Schwartz, J. M. Lacorte, H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. Amoura, G. Gorochoy, IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med* **13**, (2021).
  15. N. Dagan, N. Barda, E. Kepten, O. Miron, S. Perchik, M. A. Katz, M. A. Hernan, M. Lipsitch, B. Reis, R. D. Balicer, BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med* **384**, 1412-1423 (2021).
  16. J. Fröberg, J. Gillard, R. Philipsen, K. Lanke, J. Rust, D. van Tuijl, T. Bousema, E. Simonetti, C. E. van der Gaast – de Jongh, M. Bos, F. J. van Kuppeveld, B.-J. Bosch, M. Nabuurs-Franssen, N. van der Geest-Blankert, C. van Daal, M. A. Huynen, M. I. de Jonge, D. A. Diavatopoulos, Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms. *medRxiv*, 2021.2002.2002.21250910 (2021).
  17. M. W. Russell, Z. Moldoveanu, P. L. Ogra, J. Mestecky, Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. *Front Immunol* **11**, 611337 (2020).
  18. T. Tschernig, R. Pabst, Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. *Pathobiology* **68**, 1-8 (2000).
  19. T. J. Ketas, D. Chaturbhuj, V. M. Cruz-Portillo, E. Francomano, E. Golden, S. Chandrasekhar, G. Debnath, R. Diaz-Tapia, A. Yasmeen, W. Leconet, Z. Zhao, P. J. M.

- Brouwer, M. M. Cushing, R. W. Sanders, A. Cupo, P. J. Klasse, S. C. Formenti, J. P. Moore, Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. *bioRxiv*, (2021).
20. R. W. Y. Chan, K. C. Chan, K. Y. Y. Chan, G. C. Y. Lui, J. G. S. Tsun, R. Y. K. Wong, M. W. L. Yu, M. H. T. Wang, P. K. S. Chan, H. S. Lam, A. M. Li, SARS-CoV-2 detection by nasal strips: A superior tool for surveillance of paediatric population. *J Infect* **82**, 84-123 (2021).
21. B. Zheng, W. Peng, M. Guo, M. Huang, Y. Gu, T. Wang, G. Ni, D. Ming, Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. *Chem Eng J* **418**, 129392 (2021).
22. B. Xu, N. Wagner, L. N. Pham, V. Magno, Z. Shan, E. C. Butcher, S. A. Michie, Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways. *J Exp Med* **197**, 1255-1267 (2003).
23. F. E. Johansen, E. S. Baekkevold, H. S. Carlsen, I. N. Farstad, D. Soler, P. Brandtzaeg, Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. *Blood* **106**, 593-600 (2005).
24. K. Bahl, J. J. Senn, O. Yuzhakov, A. Bulychev, L. A. Brito, K. J. Hassett, M. E. Laska, M. Smith, O. Almarsson, J. Thompson, A. M. Ribeiro, M. Watson, T. Zaks, G. Ciaramella, Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. *Mol Ther* **25**, 1316-1327 (2017).

25. J. Froberg, D. A. Diavatopoulos, Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. *Curr Opin Infect Dis* **34**, 181-186 (2021).
26. Russell MW, Kilian M, Mantis NJ, C. s. B, in *Mucosal Immunology*. (New York, 2015), vol. 1.
27. Global Times, Sinovac says a booster shot for COVID-19 would increase antibody response tenfold within one week. *Global Times*, (2021).
28. L. Bochnia-Bueno, S. M. De Almeida, S. M. Raboni, D. Adamoski, L. L. M. Amadeu, S. Carstensen, M. B. Nogueira, SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days. *medRxiv*, 2021.2005.2020.21255825 (2021).
29. K. Murugesan, P. Jagannathan, T. D. Pham, S. Pandey, H. F. Bonilla, K. Jacobson, J. Parsonnet, J. R. Andrews, D. Weiskopf, A. Sette, B. A. Pinsky, U. Singh, N. Banaei, Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response. *Clin Infect Dis*, (2020).
30. C. W. Tan, W. N. Chia, X. Qin, P. Liu, M. I. Chen, C. Tiu, Z. Hu, V. C. Chen, B. E. Young, W. R. Sia, Y. J. Tan, R. Foo, Y. Yi, D. C. Lye, D. E. Anderson, L. F. Wang, A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **38**, 1073-1078 (2020).
31. E. J. Valcourt, K. Manguiat, A. Robinson, J. C. Chen, K. Dimitrova, C. Philipson, L. Lamoureux, E. McLachlan, Z. Schiffman, M. A. Drebot, H. Wood, Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *Diagn Microbiol Infect Dis* **99**, 115294 (2021).

32. M. E. Rebuli, A. M. Speen, P. W. Clapp, I. Jaspers, Novel applications for a noninvasive sampling method of the nasal mucosa. *Am J Physiol Lung Cell Mol Physiol* **312**, L288-L296 (2017).
33. D. K. W. Chu, Y. Pan, S. M. S. Cheng, K. P. Y. Hui, P. Krishnan, Y. Liu, D. Y. M. Ng, C. K. C. Wan, P. Yang, Q. Wang, M. Peiris, L. L. M. Poon, Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem* **66**, 549-555 (2020).

## **Acknowledgments**

We would like to acknowledge Prof Aaron HP Ho, Prof Megan YP Ho and Miss Yuan-yuan Wei (Department of Biomedical Engineering, Faculty of Engineering, The Chinese University of Hong Kong) who tailor-cut the nasal strips for this study and Ms Fiona Cheng (Department of Paediatrics, The Chinese University of Hong Kong) for her assistance in preparing all the nasal strip vials. We would like to offer our special thanks to Ms Carrie Lee and Ms Cecily Leung in collecting the biospecimens from our research subjects and all the subjects who agreed to participate in this study. We thank Dr Agnes Leung, Prof Tony Nelson and Prof Ellis KL Hon (Department of Paediatrics, The Chinese University of Hong Kong) for their continuous encouragement to the research team.

## **Funding**

Health and Medical Research Fund commissioned grants COVID190112 (RWYC)  
The Chinese University of Hong Kong Direct Grant for Research 2020.075 (RWYC)  
Hong Kong Institute of Allergy Research Grant 2020 (RWYC)

## **Author contributions**

Conceptualization: KYYC, HSL, RWYC  
Methodology: SL, JGST, KYYC, HSL, RWYC  
Investigation: SL, JGST, KCCC, KYYC, GPGF, HSL, RWYC  
Visualization: SL, JYC, JGST, KYYC, RWYC  
Funding acquisition: HSL, AML, RWYC  
Project administration: SL, JGST, KYYC, RWYC  
Supervision: KYYC, HSL, AML, RWYC  
Writing – original draft: SL, JYC, RWYC  
Writing – review & editing: KCCC, KYYC, HSL, AML, RWYC

**Competing interests:** The authors have no competing interests.